Comprehensive Pain Care, P.C., 840 Church St NE #D, Marietta, GA 30060-8937, USA.
Future Oncol. 2012 Feb;8(2):121-30. doi: 10.2217/fon.11.146.
Optimal management of breakthrough cancer pain (BTCP) requires analgesics with a rapid onset of action, consistent efficacy, improved patient acceptability and tolerability and ease of use. Fentanyl pectin nasal spray (FPNS) incorporates a proprietary pectin-based gelling agent to enhance absorption and produce a faster onset of action and consistent plasma concentration. FPNS is indicated for the treatment of breakthrough pain in cancer patients who are tolerant to opioid therapy for their underlying persistent cancer pain. FPNS has been evaluated in clinical studies in patients with BTCP and shown to be effective, safe and well tolerated. In addition, FPNS has demonstrated high levels of patient satisfaction, convenience and ease of use. FPNS therefore represents an important addition to the treatment options for BTCP.
优化爆发性癌痛（BTCP）管理需要起效迅速、疗效一致、提高患者可接受性和耐受性、使用方便的镇痛药。芬太尼果胶鼻腔喷雾剂（FPNS）采用专有的果胶基胶凝剂，以增强吸收并产生更快的起效和一致的血浆浓度。FPNS 用于治疗对其基础持续性癌痛的阿片类药物治疗耐受的癌症患者的爆发性疼痛。FPNS 已在 BTCP 患者的临床研究中进行了评估，结果表明其有效、安全且耐受性良好。此外，FPNS 还表现出较高的患者满意度、便利性和易用性。因此，FPNS 是 BTCP 治疗选择的重要补充。
